{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:29:07Z","timestamp":1793413747125,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Docetaxel is the widely-used first-line therapy to treat lung cancer around the world. However, tumor progression and severe side effect occurred in some patients with docetaxel treatment. Most of the side effects were caused by immunocompromise, which limits the long-term use of docetaxel. Shenqi Fuzheng (SQFZ) injection has been used as adjuvant therapy to treat lung cancer which may enhance immunity as well. Owing to the complexity of drug combination, the mechanism of SQFZ injection in combination with docetaxel on lung cancer remains unclear. Therefore, a network pharmacology-based strategy was proposed in this study to help solve this problem. Network pharmacology approach comprising multiple components, candidate targets of component and therapeutic targets, has been used in this study. Also, <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic> experiment was applied to verify the predicted targets from network pharmacology We established mouse lung cancer model and inject with docetaxel and SQFZ injection. Tumour weight, spleen index, thymus index, immunohistochemical staining and ELISA were conducted to evaluate the effect and underlying mechanisms of docetaxel and SQFZ injection. Besides A549 cells were also administrated by docetaxel and SQFZ.The indexes BCL2, CASP3 and CASP9 were determined after administration. The results indicated that combination of SQFZ and docetaxel could reduce tumour weight, enhance the spleen index, thymus index. Meanwhile, it could improve the activity of caspase-3 and IL-2 in mice and caspase-3, caspase-9 in A549 cell and inhibit the activity of BCL-2 in A549 cell, which verified the potential protective targets predicted by network pharmacology. In conclusion, combination of SQFZ and docetaxel could increase the curative effect by inducing tumour to apoptosis and play a key role on immunoprotection to reduce side effects.<\/jats:p>","DOI":"10.1038\/s41598-019-40954-3","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T12:06:06Z","timestamp":1552565166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Network Pharmacology-Based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Tan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Baochen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Yali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Zongxi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Wantong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du","family":"Shouying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"40954_CR1","unstructured":"Z., Habib et al. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro. J. Cell. Physiol (2018)."},{"issue":"Suppl 1","key":"40954_CR2","doi-asserted-by":"publisher","first-page":"i88","DOI":"10.1093\/bja\/aeu192","volume":"113","author":"DP Maher","year":"2014","unstructured":"Maher, D. P. et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 113(Suppl 1), i88\u201394 (2014).","journal-title":"Br J Anaesth."},{"key":"40954_CR3","doi-asserted-by":"publisher","first-page":"e30880","DOI":"10.1371\/annotation\/9975dca7-420a-425e-a513-b645b120edf8","volume":"7","author":"L Yan","year":"2012","unstructured":"Yan, L. et al. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients. PLoS ONE 7, e30880 (2012).","journal-title":"PLoS ONE"},{"key":"40954_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2165\/00003495-199651060-00011","volume":"51","author":"B Fulton","year":"1996","unstructured":"Fulton, B. & Spencer, C. M. Docetaxel, A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 51, 1075\u201392 (1996).","journal-title":"Drugs."},{"key":"40954_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","volume":"48","author":"EK Rowinsky","year":"1997","unstructured":"Rowinsky, E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48, 353\u2013374 (1997).","journal-title":"Annu. Rev. Med."},{"key":"40954_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/clpt.2009.233","volume":"87","author":"SL Koolen","year":"2010","unstructured":"Koolen, S. L., Beijnen, J. H. & Schellens, J. H. Intravenous-to-oral swith in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin Pharmacol Ther. 87, 126\u2013129 (2010).","journal-title":"Clin Pharmacol Ther."},{"key":"40954_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.9-suppl_2-3","volume":"9","author":"J Gligorov","year":"2004","unstructured":"Gligorov, J. & Lotz, J. P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 9, 3\u20138 (2004).","journal-title":"Oncologist."},{"key":"40954_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/B:BREA.0000004374.72658.17","volume":"82","author":"A Ballestrero","year":"2003","unstructured":"Ballestrero, A. et al. Dose-dense vinorelbine and paclitaxel with granulocytecolony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat. 82, 185\u2013190 (2003).","journal-title":"Breast Cancer Res Treat."},{"key":"40954_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bju.13764","volume":"119","author":"MH Poorthuis","year":"2017","unstructured":"Poorthuis, M. H., Vernooij, R. W., van Moorselaar, R. J. & de Reijke, T. M. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials. BJU International 119, 831\u2013845 (2017).","journal-title":"BJU International"},{"key":"40954_CR10","first-page":"203","volume":"21","author":"J Tang","year":"2015","unstructured":"Tang, J., He, H. & Xu, R. Meta-analysis on Treatment of Non-small Cell Lung Cancer by Shenqi Fuzheng Injection in Combination with Radiotherapy. Chinese Journal of Experimental Traditional Medical Formulate 21, 203\u2013208 (2015).","journal-title":"Chinese Journal of Experimental Traditional Medical Formulate"},{"key":"40954_CR11","first-page":"60","volume":"52","author":"M Ao","year":"2012","unstructured":"Ao, M., Lian, X. & Liu, C. Effect of Shenqi Fuzheng injection on hematopoietic function and immune function in patients with lung cancer undergoing chemotherapy. Shandong Medical Journal. 52, 60\u201361 (2012).","journal-title":"Shandong Medical Journal."},{"key":"40954_CR12","first-page":"309","volume":"24","author":"S Wu","year":"2011","unstructured":"Wu, S., Zhu, H. & Wei., M. The Therapeutic Observation of Shenqi Fuzheng Injection in Radiotherapy for Esophageal Carcinoma. Journal of Basic and Clinical Oncology. 24, 309\u2013310 (2011).","journal-title":"Journal of Basic and Clinical Oncology."},{"key":"40954_CR13","first-page":"2083","volume":"17","author":"Y Lu","year":"2006","unstructured":"Lu, Y. & Lu, Y. Pharmacological action and clinical application of Shenqi Fuzheng injection. Shizhen medicine and materia medica research. 17, 2083\u20132085 (2006).","journal-title":"Shizhen medicine and materia medica research."},{"key":"40954_CR14","first-page":"13","volume":"4","author":"Y Jia","year":"2012","unstructured":"Jia, Y. & Huang, Y. Efficacy of Shenqi Fuzheng injection in advanced non-small cell lung chemotherapy in elderly patients. Clinical research of traditional Chinese medicine. 4, 13\u201315 (2012).","journal-title":"Clinical research of traditional Chinese medicine."},{"key":"40954_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1631\/jzus.B1600357","volume":"18","author":"D Boyu","year":"2017","unstructured":"Boyu, D. et al. Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells. J Zhejiang Univ Sci B. 18, 76\u201378 (2017).","journal-title":"J Zhejiang Univ Sci B."},{"key":"40954_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.biopha.2018.04.054","volume":"105","author":"Z Baochen","year":"2018","unstructured":"Baochen, Z. et al. Network pharmacology-based identification of protective mechanism of Panax Notoginseng Saponins on aspirin induced gastrointestinal injury. Biomedicine & Pharmacotherapy 105, 159\u2013166 (2018).","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"07","key":"40954_CR17","first-page":"1494","volume":"35","author":"H-yan Gu","year":"2013","unstructured":"Gu, H.-yan et al. Chemical constituents of Shenqi Fuzheng Injection(II). Chinese Traditional Patent. Medicine. 35(07), 1494\u20131499 (2013).","journal-title":"Medicine."},{"key":"40954_CR18","first-page":"1743","volume":"33","author":"Z Sheng-yuan","year":"2011","unstructured":"Sheng-yuan, Z. et al. Chemical constituents of Shenqi Fuzheng Injection. Chinese Traditional Patent. Medicine. 33, 1743\u20131747 (2011).","journal-title":"Medicine."},{"key":"40954_CR19","first-page":"4275","volume":"27","author":"S Juan","year":"2016","unstructured":"Juan, S. & Shengbin, Y. Simultaneous Determination of Six Components in Shenqi Fuzheng Injection by HPLC. China. Pharmacy. 27, 4275\u20134277 (2016).","journal-title":"Pharmacy."},{"key":"40954_CR20","unstructured":"Haiyan, X., Wenhua, H. & Yangang, S. Determination of radix codonopsis in Shenqi Fuzheng Injection by UHPLC-MS. Journal of Chinese Medicinal Materials. 37, 1471\u20131474 (2014)."},{"key":"40954_CR21","first-page":"19","volume":"11","author":"W Di","year":"2009","unstructured":"Di, W. et al. Efficienct Components Analysis of Shenqi Fuzheng Injection. Modern Chinese Medicine. 11, 19\u201322\u2009+\u200943 (2009).","journal-title":"Modern Chinese Medicine."},{"key":"40954_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cyto.2009.05.014","volume":"47","author":"K Joshua","year":"2009","unstructured":"Joshua, K. Ko, Cecilia Wai Shan Chik. Protective action of radix Astragalus membranaceus against hapten-induced through modulation of cytokines. Cytokines. 47, 85 (2009).","journal-title":"Cytokines."},{"key":"40954_CR23","first-page":"263","volume":"23","author":"YP Wang","year":"2002","unstructured":"Wang, Y. P., Li, X. Y. & Song, C. Q. Effect of astragaloside IV on T,B lymphocyte proliferation and peritoneal macrophage function in mice. Acta Pharmacol Sinica. 23, 263 (2002).","journal-title":"Acta Pharmacol Sinica."},{"key":"40954_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jep.2004.08.036","volume":"96","author":"E Yesilada","year":"2005","unstructured":"Yesilada, E., Bedir, E., Cali, I., Takaishi, Y. & Ohmoto, Y. Effect if triterpene saponins from Astragalus species on vitro cytokine release. Jounnal of Ethnopharmacology. 96, 71 (2005).","journal-title":"Jounnal of Ethnopharmacology."},{"key":"40954_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ijbiomac.2008.06.009","volume":"43","author":"YX Sun","year":"2008","unstructured":"Sun, Y. X. & Liu, J. C. Structural charcterization of a water-soluble polysaccharide from the Roots of Codonopsis pilosula and its immunity activity. Int J Biol Macromol. 43, 279\u2013282 (2008).","journal-title":"Int J Biol Macromol."},{"key":"40954_CR26","first-page":"5121538","volume":"2017","author":"Y Yang","year":"2017","unstructured":"Yang, Y. et al. Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2017, 5121538 (2017).","journal-title":"Evid Based Complement Alternat Med."},{"key":"40954_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/nrm1496","volume":"5","author":"SJ Riedl","year":"2004","unstructured":"Riedl, S. J. & Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5, 897\u2013907 (2004).","journal-title":"Nat Rev Mol Cell Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40954-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40954-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:47:17Z","timestamp":1671263237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40954-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40954"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40954-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"10 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4533"}}